Marie Mazur

Dr. Mazur is a global business executive with over 30 years of experience growing revenue and profits for major vaccine and pharmaceutical companies.

Since 2006, Dr. Mazur held executive roles at the influenza vaccine company Seqirus⃰, which is part of CSL Limited, an $8.4 billion biotechnology company engaged in life-saving innovative products and vaccines. Most recently Dr. Mazur was Vice President, Pandemic Response Solutions where she had global commercial responsibility for pandemic and pre-pandemic contracts. During her tenure, Seqirus became global leader in pandemic vaccine response. In January 2018, she was selected as Co-Chair of BDPAC (Bio-Defense Policy Advisory Committee) at the Biotechnology Innovation Organization (BIO), working with biotechnology company leaders invested in the development and manufacture of medical countermeasures. Prior to joining CSL, she held successive global commercial leadership positions at GlaxoSmithKline Biologicals, 3M Pharmaceuticals and Sanofi Pasteur. Dr. Mazur holds a doctorate in Pharmacy and master's degree in Regulatory Affairs from Paris (France) University of Pharmacy, and an International Executive Degree in Business Administration from INSEAD (IEP).